Clinical trial · Observational
Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia
Open, Non-Interventional, Multicentre Trial of Rituximab in Combination With FC for the First-Line Therapy of Patients With Chronic Lymphocytic Leukaemia
NCT02461316CI-TRIAL-00024697completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of safety profile and tolerability of MabThera (rituximab) in combination with chemotherapy (fludarabine and cyclophosphamide) in the treatment of Chronic Lymphocytic Leukemia (CLL).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer | Lymphoid Leukemia | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Combination Treatment in Chronic Lymphocytic Leukemia (CLL)
- description
- All participants receiving combination treatment in Chronic Lymphocytic Leukemia (CLL)
- interventionNames
- Other: No intervention
Primary outcomes (2)
- measure
- Percentage of Adverse Events (AEs)
- timeFrame
- From baseline to end of study up to 18 months
- measure
- Percentage of Serious Adverse Events (SAEs)
- timeFrame
- From baseline to end of study up to 18 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients older than 18 years with diagnosed Chronic Lymphocytic Leukemia (CLL) * CLL stages: Binet stage C (Rai III or IV), Binet stage B (Rai I and II) requiring treatment Exclusion Criteria: \- Patients who are not eligible for rituximab treatment according to Summary of Product Characteristics (SmPC)
References
Publications (0)
Data not yet available
No reference posted for this study.